Literature DB >> 2755309

Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C.

J Hofmann1, F Ueberall, L Posch, K Maly, D B Herrmann, H Grunicke.   

Abstract

The new phospholipid analogue 3-hexadecylmercapto-2-methoxy-methyl-propyl-1-phosphocholine inhibits the phospholipid-calcium-dependent protein kinase, partially purified from Walker carcinoma cells with a Ki value of 0.56 microM. The compound inhibits the phorbol ester stimulated phosphorylation of the ribosomal protein S6 indicating that the depression of Ca2+-phospholipid-dependent protein kinase by the alkyl phospholipid also occurs in intact cells. The dose effect curve for the inhibition of cell proliferation by 3-hexadecylmercapto-2-methoxy-methyl-propyl-1-phosphocholine in Walker cells exhibits a close correlation to the dose effect curve for the depression of Ca2+-phospholipid-dependent protein kinase activity. Although alternative mechanisms cannot be excluded, the data suggest that the growth inhibitory activity of 3-hexadecylmercapto-2-methoxy-methyl-propyl-1-phosphocholine correlates with the inhibition of Ca2+-phospholipid-dependent protein kinase. The antiproliferative activity of 3-hexadecylmercapto-2-methoxy-methyl-propyl-1-phosphocholine is synergistically enhanced by cis-diamminedichloroplatinum(II).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2755309     DOI: 10.1007/BF02535169

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  28 in total

1.  Selective inhibition of thymidine transport at low doses of the alkylating agents triethyleneiminobenzoquinone (Trenimon).

Authors:  H Grunicke; F Hirsch; H Wolf; U Bauer; G Kiefer
Journal:  Exp Cell Res       Date:  1975-02       Impact factor: 3.905

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Eur J Biochem       Date:  1981-03-16

Review 4.  Studies and perspectives of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

Review 5.  Anti-tumor action of alkyl-lysophospholipids (Review).

Authors:  W E Berdel; W R Bausert; U Fink; J Rastetter; P G Munder
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

6.  A metabolite of an antineoplastic ether phospholipid may inhibit transmembrane signalling via protein kinase C.

Authors:  W J van Blitterswijk; R L van der Bend; I M Kramer; A J Verhoeven; H Hilkmann; J de Widt
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

7.  Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro.

Authors:  W E Berdel; R Korth; A Reichert; W J Houlihan; U Bicker; H Nomura; W R Vogler; J Benveniste; J Rastetter
Journal:  Anticancer Res       Date:  1987 Nov-Dec       Impact factor: 2.480

8.  Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

Authors:  S Shionoya; Y Lu; K J Scanlon
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

9.  Alkyl-lysophospholipids inhibit the growth of hypernephroid carcinomas in vitro.

Authors:  W E Berdel; U Fink; B Egger; A Reichert; P G Munder; J Rastetter
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

10.  Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells.

Authors:  D R Hoffman; L H Hoffman; F Snyder
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

View more
  12 in total

1.  Phase I trial of ilmofosine as a 24 hour infusion weekly.

Authors:  M von Mehren; B J Giantonio; C McAleer; R Schilder; J McPhillips; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 2.  Alkylphosphocholines: a new class of membrane-active anticancer agents.

Authors:  P Hilgard; T Klenner; J Stekar; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II).

Authors:  K Nishio; Y Sugimoto; Y Fujiwara; T Ohmori; T Morikage; Y Takeda; M Ohata; N Saijo
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

Review 4.  Therapeutic potential of protein kinase C inhibitors.

Authors:  D Bradshaw; C H Hill; J S Nixon; S E Wilkinson
Journal:  Agents Actions       Date:  1993-01

Review 5.  Role of protein kinases in antitumor drug resistance.

Authors:  H Grunicke; J Hofmann; I Utz; F Uberall
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

6.  Antitumor activity of Ilmofosine (BM 41.440) in the 3Lewis-lung carcinoma model.

Authors:  D B Herrmann; H G Opitz; P G Munder
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Comparison of selective cytotoxicity of alkyl lysophospholipids.

Authors:  W R Vogler; A C Olson; S Okamoto; M Shoji; R L Raynor; J F Kuo; W E Berdel; H Eibl; J Hajdu; H Nomura
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.

Authors:  S Akinaga; K Nomura; K Gomi; M Okabe
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Membrane-interactive lipids as experimental anticancer drugs.

Authors:  W E Berdel
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

Review 10.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.